Advertisement

Der Hautarzt

, Volume 70, Issue 12, pp 942–947 | Cite as

Aryl-Hydrocarbon-Rezeptor als Zielstruktur für neue Medikamente bei Psoriasis und atopischer Dermatitis

  • Hans F. MerkEmail author
Leitthema
  • 93 Downloads

Zusammenfassung

Teerhaltige Externa wurden über Jahrhunderte bei chronischen Entzündungen der Haut verwendet. Inzwischen wurde erkannt, dass der Aryl-Hydrocarbon-Rezeptor (AhR) die entscheidende Zielstruktur ist, über den die Wirkung der Teerprodukte sowohl gegen die Entzündung wie auch gegen die Barriereschädigung der Haut ermöglicht wird. In ersten klinischen Studien ließ sich nun zeigen, dass Tapinarof als Ligand des AhR, der nicht zu den aufgrund ihrer kanzerogenen Eigenschaften unerwünschten Substanzen in Teerprodukten zählt, erwünschte therapeutische Effekte bei Psoriasis und atopischer Dermatitis hat. Da viele AhR-Liganden bekannt sind, könnte dieses Tar-smart-Produkt ein erstes Beispiel einer neuen Medikamentengruppe zur Behandlung von entzündlichen und mit einer Barriereschädigung einhergehenden Hauterkrankungen sein.

Schlüsselwörter

Tapinarof Teerprodukte Tar-smart-Produkt Chronisch entzündliche Hauterkrankungen Barriereschädigung 

The aryl hydrocarbon receptor as the target structure for new drugs in psoriasis and atopic dermatitis

Abstract

Coal tar therapy was used for centuries to treat skin disorders characterised by inflammation and skin barrier damage. It has been shown that the aryl hydrocarbon receptor (AhR) is the key target structure for these pharmacological effects of coal tar. Since coal tar has been used less and less because of the carcinogenicity of many ingredients of coal tar, other ligands of AhR were studied. Tapinarof is such a ligand and proved to be a promising new drug to treat psoriasis and atopic dermatitis. Since many endogenous and exogenous ligands of AhR are known, it may be that this “tar-smart” product is a first example of a new drug family with which dermatologists can treat skin disorders that are characterized by inflammation and skin barrier damage.

Keywords

Tapinarof Coal tar products Tar-smart product Chronic inflammatory skin diseases Skin barrier damage 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

H.F. Merk gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Bickers DR, Das M, Mukhtar H (1986) Pharmacological modification of epidermal detoxification systems. Br J Dermatol 115(Suppl 31):9–1PubMedGoogle Scholar
  2. 2.
    Bickers DR, Kappas A (1978) Human skin aryl hydrocarbon hydroxylase. Induction by coal tar. J Clin Invest 62(5):1061–1068PubMedPubMedCentralGoogle Scholar
  3. 3.
    Bickers DR, Wroblewski D, Tapu-Dutta-Choudhury, Mukhtar H (1982) Induction of neonatal rat skin and liver aryl hydrocarbon hydroxylase by coal tar and its constituents. J Invest Dermatol 78(3):227–229PubMedGoogle Scholar
  4. 4.
    Bickers DR (1981) The carcinogenicity and mutagenicity of therapeutic coal tar—a perspective. J Invest Dermatol 77(2):173–174PubMedGoogle Scholar
  5. 5.
    Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, Lyle M (2012) Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol 26(12):1516–1521PubMedGoogle Scholar
  6. 6.
    Bissonnette R, Chen G, Bolduc C, Maari C, Lyle M, Tang L, Webster J, Zhou Y (2010) Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 146(4):446–449PubMedGoogle Scholar
  7. 7.
    Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M (2012) Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol 166(4):853–860PubMedGoogle Scholar
  8. 8.
    Bissonnette R, Vasist LS, Bullman JN, Collingwood T, Chen G, Maeda-Chubachi T (2018) Systemic Pharmacokinetics, safety, and preliminary efficacy of topical ahR agonist Tapinarof: results of a phase 1 study. Clin Pharmacol Drug Dev 7(5):524–531.  https://doi.org/10.1002/cpdd.439 CrossRefPubMedGoogle Scholar
  9. 9.
    Czarnowicki T, Malajian D, Khattri S, Correa da Rosa J, Dutt R, Finney R, Dhingra N, Xiangyu P, Xu H, Estrada YD, Zheng X, Gilleaudeau P, Sullivan-Whalen M, Suaréz-Fariñas M, Shemer A, Krueger JG, Petrolatum G‑YE (2016) Barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol 137(4):1091–1102PubMedGoogle Scholar
  10. 10.
    Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, Villanova F, Tosi I, Hirota K, Nestle FO, Mrowietz U, Gilchrist MJ, Stockinger B (2014) Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 19;40(6):989–1001Google Scholar
  11. 11.
    Esser C, Bargen I, Weighardt H, Haarmann-Stemmann T, Krutmann J (2013) Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol 35(6):677–691PubMedGoogle Scholar
  12. 12.
    Esser C, Rannug A, Stockinger B (2009) The aryl hydrocarbon receptor in immunity. Trends Immunol 30(9):447–454PubMedGoogle Scholar
  13. 13.
    Esser C, Rannug A (2015) The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev 67(2):259–279PubMedGoogle Scholar
  14. 14.
    Fritsche E, Schäfer C, Calles C, Bernsmann T, Bernshausen T, Wurm M, Hübenthal U, Cline JE, Hajimiragha H, Schroeder P, Klotz LO, Rannug A, Fürst P, Hanenberg H, Abel J, Krutmann J (2007) Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A 22;104(21):8851–8856Google Scholar
  15. 15.
    Goerz G, Merk H, Hölzle E (1985) Teerbehandlung bei Psoriasis. Hautarzt 36(1):50–53PubMedGoogle Scholar
  16. 16.
    Goerz G, Merk H (1983) Teerbehandlung in der Dermatologie. Hautarzt 34(9):437–441PubMedGoogle Scholar
  17. 17.
    Haarmann-Stemmann T, Esser C, Krutmann J (2015) The Janus-faced role of Aryl hydrocarbon receptor signaling in the skin: consequences for prevention and treatment of skin disorders. J Invest Dermatol 135(11):2572–2576PubMedGoogle Scholar
  18. 18.
    Haas K, Weighardt H, Deenen R, Köhrer K, Clausen B, Zahner S, Boukamp P, Bloch W, Krutmann J, Esser C (2016) Aryl hydrocarbon receptor in Keratinocytes is essential for murine skin barrier integrity. J Invest Dermatol 136(11):2260–2269PubMedGoogle Scholar
  19. 19.
    Hahn ME, Karchner SI, Merson RR (2017) Diversity as opportunity: Insights from 600 million years of AhR evolution. Curr Opin Toxicol 2:58–71PubMedPubMedCentralGoogle Scholar
  20. 20.
    Heymann WR (2019) “Tar smarts” may have a new meaning for atopic dermatitis and psoriasis. J Am Acad Dermatol 80:56–57PubMedGoogle Scholar
  21. 21.
    Johnston A (2017) Resolving inflammation by targeting an ancient innate immune sensor with a bacterial metabolite. J Invest Dermatol 137(10):2050–2052PubMedGoogle Scholar
  22. 22.
    Khan WA, Park SS, Gelboin HV, Bickers DR, Mukhtar H (1989) Monoclonal antibodies directed characterization of epidermal and hepatic cytochrome P‑450 isozymes induced by skin application of therapeutic crude coal tar. J Invest Dermatol 93(1):40–45PubMedGoogle Scholar
  23. 23.
    Leijs MM, Koppe JG, Kraus T, Baron JM, Merk HF (2018) POPs and skin. In: Krutmann J, Merk HF (Hrsg) Environment and Skin. Springer, Heidelberg, S 113–130Google Scholar
  24. 24.
    Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, Galanou M, Vlachos C, Stathopoulou K, Skaltsounis AL, Marselos M, Velegraki A, Denison MS, Bassukas ID (2013) Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol 133(8):2023–2030PubMedPubMedCentralGoogle Scholar
  25. 25.
    McLean WH, Irvine AD (2013) Old King Coal—molecular mechanisms underlying an ancient treatment for atopic dermatitis. J Clin Invest 123:551–553PubMedPubMedCentralGoogle Scholar
  26. 26.
    Merk HF, Mukhtar H, Kaufmann I, Das M, Bickers DR (1987) Human hair follicle benzo[a]pyrene and benzo[a]pyrene 7,8-diol metabolism: effect of exposure to a coal tar-containing shampoo. J Invest Dermatol 88(1):71–76PubMedGoogle Scholar
  27. 27.
    Merk HF, Barrier Skin MHF, Krutmann IJ (Hrsg) (2018) Environment and Skin. Springer, Heidelberg, S 3–10Google Scholar
  28. 28.
    Merk HF (2016) Zentraler Sensor für Umwelteinflüsse. Allergo J Int 25:82–84Google Scholar
  29. 29.
    Mukhtar H, Asokan P, Das M, Santella RM, Bickers DR (1986) Benzo(a)pyrene diol epoxide-I-DNA adduct formation in the epidermis and lung of SENCAR mice following topical application of crude coal tar. Cancer Lett 33(3):287–294PubMedGoogle Scholar
  30. 30.
    Mukhtar H, Link CM, Cherniack E, Kushner DM, Bickers DR (1982) Effect of topical application of defined constituents of coal tar on skin and liver aryl hydrocarbon hydroxylase and 7‑ethoxycoumarin deethylase activities. Toxicol Appl Pharmacol 64(3):541–549PubMedGoogle Scholar
  31. 31.
    Navid F, Bruhs A, Schuller W, Fritsche E, Krutmann J, Schwarz T, Schwarz A (2013) The Aryl hydrocarbon receptor is involved in UVR-induced immunosuppression. J Invest Dermatol 133(12):2763–2770PubMedGoogle Scholar
  32. 32.
    Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197–120PubMedGoogle Scholar
  33. 33.
    Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, Kraus JE (2019) A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol 80(1):89–98PubMedGoogle Scholar
  34. 34.
    Rannug A, Fritsche E (2006) The aryl hydrocarbon receptor and light. Biol Chem 387(9):1149–1157PubMedGoogle Scholar
  35. 35.
    Robbins K, Bissonnette R, Maeda-Chubachi T, Ye L, Peppers J, Gallagher K, Kraus JE (2019) Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol 80(3):714–721Google Scholar
  36. 36.
    Roelofzen JH, Aben KK, Oldenhof UT, Coenraads PJ, Alkemade HA, van de Kerkhof PC, van der Valk PG, Kiemeney LA (2010) No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol 130(4):953–961PubMedGoogle Scholar
  37. 37.
    Roelofzen JH, van der Valk PG, Godschalk R, Dettbarn G, Seidel A, Golsteijn L, Anzion R, Aben KK, van Schooten FJ, Kiemeney LA, Scheepers PT (2012) DNA adducts in skin biopsies and 1‑hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicol Lett 213(1):39–44PubMedGoogle Scholar
  38. 38.
    Roelofzen JHJ, Aben KKH, Van de Kerkhof PCM, Van de Valk PGM, Kiemeney LALM (2015) Dermatological exposure to coal tar and bladder cancer risk: a case-control study. Urol Oncol 33(1):20.e19–20.e20Google Scholar
  39. 39.
    Santella RM, Nunes MG, Blaskovic R, Perera FP, Tang D, Beachman A, Lin JH, DeLeo VA (1994) Quantitation of polycyclic aromatic hydrocarbons, 1‑hydroxypyrene, and mutagenicity in urine of coal tar-treated psoriasis patients and untreated volunteers. Cancer Epidemiol Biomarkers Prev 3(2):137–140PubMedGoogle Scholar
  40. 40.
    Smirnova A, Wincent E, Vikström Bergander L, Alsberg T, Bergman J, Rannug A, Rannug U (2016) Evidence for new light-independent pathways for generation of the endogenous Aryl hydrocarbon receptor agonist FICZ. Chem Res Toxicol 19;29(1):75–86Google Scholar
  41. 41.
    Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Coquery CM, Neil J, Pryor WM, Mayhew D, Rajpal DK, Creech K, Furst S, Lee J, Wu D, Rastinejad F, Willson TM, Viviani F, Morris DC, Moore JT, Cote-Sierra J (2017) Tapinarof is a natural ahR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol 137(10):2110–2119PubMedGoogle Scholar
  42. 42.
    van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems IM, Hato SV, van der Valk PG, Schröder JM, Joosten I, Zeeuwen PL, Schalkwijk J (2013) Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 123(2):917–927PubMedPubMedCentralGoogle Scholar
  43. 43.
    van den Bogaard EH, Podolsky MA, Smits JP, Cui X, John C, Gowda K, Desai D, Amin SG, Schalkwijk J, Perdew GH, Glick AB (2015) Genetic and pharmacological analysis identifies a physiological role for the AHR in epidermal differentiation. J Invest Dermatol 135(5):1320–1328PubMedPubMedCentralGoogle Scholar
  44. 44.
    Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 1;453(7191):106–109Google Scholar
  45. 45.
    Yu J, Luo Y, Zhu Z, Zhou Y, Sun L, Gao J, Sun J, Wang G, Yao X, Li W (2019) A tryptophan metabolite of the skin microbiota attenuates inflammation in patients with atopic dermatitis through the aryl hydrocarbon receptor. J Allergy Clin Immunol 143(6):2108–2119PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Dermatologie und Allergologie – HautklinikUniversitätsklinikum AachenAachenDeutschland

Personalised recommendations